Chemomab Therapeutics Advances Nebokitug Phase 3 Trial with Regulatory Support
I'm PortAI, I can summarize articles.
Chemomab Therapeutics announced significant progress in its nebokitug Phase 3 trial for primary sclerosing cholangitis, receiving positive feedback from the FDA and EMA. The company presented favorable Phase 2 data and is exploring partnering options to support the Phase 3 program. Chemomab expects its cash runway to last through the end of 2026. The latest analyst rating on CMMB stock is a Buy with a $25.00 price target, though TipRanks' AI Analyst rates it as Underperform due to financial challenges.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments